Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Revance's Long-Acting RT002 Will Have Slow-Moving Impact On Allergan

Dec 06 2017

• By Mandy Jackson

Syringes stuck in a dartboard

Related Content

Allergan Readies Cost Cuts As Restasis Generics Approach

Nov 02 2017

Allergan May Rue Mohawk Tribe Deal As Court Invalidates Restasis Patents

Oct 17 2017

VENUS II Paves Way For Allergan's Ulipristal NDA In Uterine Fibroids

Jan 18 2017

Related Companies

Revance Therapeutics, Inc.

Allergan plc

Galderma S.A.

Merz Pharmaceuticals GmbH

Additional Topics

Clinical Trials Business Strategies Research & Development Aesthetics BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.